News
-
-
PRESS RELEASE
EQS-Adhoc: CANCOM SE: Termination of the 2025 share buyback programme, cancellation of treasury shares and capital reduction
CANCOM SE terminates 2025 share buyback program, cancels treasury shares, and reduces capital ahead of Annual General Meeting. Insider info disclosed in accordance with MAR -
PRESS RELEASE
Mutares enters next phase of growth: Record-breaking pipeline on both the buy and sell sides meets strong results and maximum capital market support
Mutares SE & Co. KGaA announces record-breaking growth phase with strong results, significant exit pipeline, and successful capital increase amid capital market support -
PRESS RELEASE
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients
OSE Immunotherapeutics welcomes FDA Orphan Drug Designation granted to Pegrizeprument (VEL-101) for prevention of organ rejection in heart transplant patients, a novel immunomodulatory treatment developed in partnership with Veloxis Pharmaceuticals -
-
PRESS RELEASE
FORVIA: CHANGES TO THE COMPOSITION OF THE BOARD OF DIRECTORS OF FORVIA SUBJECT TO APPROVAL BY THE 2026 ANNUAL GENERAL MEETING
FORVIA announces changes in Board of Directors composition with Pierre-André de Chalendar appointment and resignation of Michel de Rosen. Details on the 2026 Annual General Meeting -
-
PRESS RELEASE
FORVIA : CHANGEMENTS DANS LA COMPOSITION DU CONSEIL D'ADMINISTRATION DE FORVIA SOUMIS A L'APPROBATION DE SON ASSEMBLEE GENERALE ANNUELLE 2026
Réorganisation du Conseil d'administration de FORVIA avec la nomination de Pierre-André de Chalendar en remplacement de Michel de Rosen. FORVIA, société internationale de technologie automobile, annonce des changements clés -
PRESS RELEASE
Exosens delivers strong Q1 2026 performance, with accelerating defense momentum in digital imaging and night vision; Fully on track to deliver on 2026 guidance
Exosens reports strong Q1 2026 performance with accelerating defense momentum in digital imaging and night vision. On track to deliver on 2026 guidance -
